$NTRA News

BTIG Maintains Buy on Natera, Raises Price Target to $430

Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA): Signatera Momentum Strengthens Growth Outlook

Natera Highlights New Signatera Genome Assay Data At ESMO 2026, With ctDNA Dynamics Predictive Of Survival Outcomes In Bladder Cancer

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today

Natera (NTRA) Is Expanding Cancer Testing Rapidly. Does Its Valuation Leave Room for Error?

Why Natera (NTRA) Stock Is Up Today

Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $500

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435

TD Cowen Maintains Buy on Natera, Raises Price Target to $480

Natera Reports Q2 2026 Results: Full Earnings Call Transcript

How FDA Breakthrough Status For Natera’s Multi‑Cancer Test (NTRA) Has Changed Its Investment Story

Natera (NTRA) Stock May Be 33% Below Fair Value Despite FDA Breakthrough News

Natera (NTRA) Could Be 33% Undervalued Following FDA Breakthrough Device Designation

Why Natera (NTRA) Stock Is Up Today

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay